Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(₁₄₅) or Lys(₁₄₆) from fPSA without internal cleavages at Lys(₁₄₅) or Lys(₁₄₆).

Peltola MT, Niemelä P, Alanen K, Nurmi M, Lilja H, Pettersson K.

J Immunol Methods. 2011 Jun 30;369(1-2):74-80. doi: 10.1016/j.jim.2011.04.006. Epub 2011 Apr 28.

3.

Phage display aided improvement of a unique prostate-specific antigen (PSA) antibody unreactive with Lys(145)-Lys(146) internally cleaved forms.

Liton MF, Peltola MT, Vehniäinen M, Kuusela E, Pettersson T, Lamminmäki U, Pettersson K, Brockmann EC.

J Immunol Methods. 2015 Jul;422:72-9. doi: 10.1016/j.jim.2015.04.005. Epub 2015 Apr 15.

PMID:
25889751
4.

Percent free PSA as an additional measure in a prostate cancer screen.

Miele ME.

Clin Lab Sci. 2001 Spring;14(2):102-7.

PMID:
15625982
5.
6.

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.

Haese A, Graefen M, Steuber T, Becker C, Pettersson K, Piironen T, Noldus J, Huland H, Lilja H.

Prostate. 2001 Oct 1;49(2):101-9.

PMID:
11582588
7.

Proximity ligation measurement of the complex between prostate specific antigen and alpha1-protease inhibitor.

Zhu L, Koistinen H, Landegren U, Stenman UH.

Clin Chem. 2009 Sep;55(9):1665-71. doi: 10.1373/clinchem.2009.127779. Epub 2009 Jul 30.

8.

Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.

Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Huber A, Lümmen G, Tscholl R.

Urology. 2000 Apr;55(4):481-5.

PMID:
10736487
9.

Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.

Lein M, Jung K, Elgeti U, Petras T, Stephan C, Brux B, Sinha P, Winkelmann B, Schnorr D, Loening S.

Eur Urol. 2001 Jan;39(1):57-64.

PMID:
11173940
10.

Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.

Lein M, Jung K, Elgeti U, Brux B, Sinha P, Schnorr D, Loening SA.

Anticancer Res. 2000 Nov-Dec;20(6D):4997-5001.

PMID:
11326657
11.
12.
13.
14.

Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.

Steuber T, Niemela P, Haese A, Pettersson K, Erbersdobler A, Felix Chun KH, Graefen M, Kattan MW, Huland H, Lilja H.

Prostate. 2005 Apr 1;63(1):13-8.

PMID:
15378521
15.

Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?

Jung K, Elgeti U, Lein M, Brux B, Sinha P, Rudolph B, Hauptmann S, Schnorr D, Loening SA.

Clin Chem. 2000 Jan;46(1):55-62.

17.

Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays.

Vessella RL, Lange PH, Partin AW, Chan DW, Sokoll LJ, Sasse EA, Crawford ED.

Urology. 2000 Jun;55(6):909-14.

PMID:
10840107
18.

Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications.

Jung K, Brux B, Lein M, Rudolph B, Kristiansen G, Hauptmann S, Schnorr D, Loening SA, Sinha P.

Clin Chem. 2000 Jan;46(1):47-54.

19.

Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.

Haese A, Vaisanen V, Lilja H, Kattan MW, Rittenhouse HG, Pettersson K, Chan DW, Huland H, Sokoll LJ, Partin AW.

J Urol. 2005 Mar;173(3):752-6.

PMID:
15711262
20.

A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases.

Stephan C, Kahrs AM, Cammann H, Lein M, Schrader M, Deger S, Miller K, Jung K.

Prostate. 2009 Feb 1;69(2):198-207. doi: 10.1002/pros.20872.

PMID:
18942119
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk